{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0075912\nAge: 77\nGender: Male\nSample ID: P-0075912-T01-IM7\nGene Panel: IMPACT505\nCancer Type: Prostate Adenocarcinoma\nSample Type: Primary\nTumor Purity: 60.0%\n=============\nDNA Variants:\nFOXA1 c.1231C>G (p.Q411E) - in 29.00% of 917 reads\nCNA Data:\nPTEN - Homozygous Deletion\nStructural Variants:\nTMPRSS2 - ERG (DELETION)\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer\",\n    \"Disease Phase or Condition\": \"Metastatic castration-resistant prostate cancer (mCRPC)\",\n    \"Drug Name\": \"Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n    \"Genomic Features\": [\n      \"CHEK1 somatic variant\",\n      \"BRIP1 somatic variant\",\n      \"RAD54L somatic variant\",\n      \"RAD51C somatic variant\",\n      \"ATM somatic variant\",\n      \"RAD51D somatic variant\",\n      \"RAD51B somatic variant\",\n      \"CHEK2 somatic variant\"\n    ],\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  }\n}"
}